Joint Basis for FDA/HHS Marijuana Rescheduling Recommendation Unveiled
FDA Law Blog: Biosimilars
JANUARY 18, 2024
Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. chemotherapy-induced), pain, and post-traumatic stress disorder.
67 
Let's personalize your content